Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Ocrevus“
Suchtreffer
Begriffe & Kennungen
Ocrevus · 4.8 · Immunoglobulins
Eintrag öffnenOcrevus · 4.8 · Immunoglobulins
Eintrag öffnenOcrevus · 4.8 · In OCARINA II, 118 patients (ocrelizumab-naïve) received the first injection of the product. The most common s
Eintrag öffnenOcrevus · 4.8 · In RMS, a decrease in lymphocyte < LLN was observed in 20.7% of patients treated with intravenous ocrelizumab
Eintrag öffnenOcrevus · 4.8 · In RMS, a decrease in lymphocyte < LLN was observed in 20.7% of patients treated with ocrelizumab compared wit
Eintrag öffnenOcrevus · 4.8 · In a placebo-controlled phase IIIb study in patients with PPMS (Study WA40404), COVID-19 was observed more fre
Eintrag öffnenOcrevus · 4.8 · In a placebo-controlled phase IIIb study in patients with PPMS (Study WA40404), COVID-19 was observed more fre
Eintrag öffnenOcrevus · 4.8 · In a randomised, double-blind, active comparator-controlled trial of flexible duration (at least 24 weeks; med
Eintrag öffnenOcrevus · 4.8 · In a study (MA30143 Shorter Infusion Substudy) designed to characterise the safety profile of shorter (2-hour)
Eintrag öffnenOcrevus · 4.8 · In active-controlled (RMS) clinical trials, IRR was the most common adverse reaction in the ocrelizumab treatm
Eintrag öffnenOcrevus · 4.8 · In active-controlled (RMS) clinical trials, herpes infections were reported more frequently in intravenous ocr
Eintrag öffnenOcrevus · 4.8 · In active-controlled (RMS) clinical trials, herpes infections were reported more frequently in ocrelizumab tre
Eintrag öffnenOcrevus · 4.8 · In line with the previous analysis of risk factors for SIs in auto-immune conditions other than MS (see sectio
Eintrag öffnenOcrevus · 4.8 · In line with the previous analysis of risk factors for SIs in auto-immune conditions other than MS (see sectio
Eintrag öffnenOcrevus · 4.8 · In paediatric patients, the most common symptoms associated with IRRs included headache, throat irritation, pr
Eintrag öffnenOcrevus · 4.8 · In the RMS clinical trials, 39.9% of ocrelizumab treated patients and 33.2% interferon beta-1-a treated patien
Eintrag öffnenOcrevus · 4.8 · In the active-controlled (RMS) treatment period, a decrease in neutrophils < LLN was observed in 14.7% of pati
Eintrag öffnenOcrevus · 4.8 · In the active-controlled (RMS) treatment period, a decrease in neutrophils < LLN was observed in 14.7% of pati
Eintrag öffnenOcrevus · 4.8 · In the active-controlled studies in RMS, infections occurred in 58.5% of patients receiving intravenous ocreli
Eintrag öffnenOcrevus · 4.8 · In the active-controlled studies in RMS, infections occurred in 58.5% of patients receiving ocrelizumab vs 52.
Eintrag öffnen